RNTX

Rein Therapeutics Inc. (RNTX) ESG Analysis Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.8 (Moderate)

RNTX provides no disclosed R&D-to-revenue intensity in the supplied metrics, limiting evidence of peer-leading low-carbon or resource-efficiency investment versus biotech peers.

The absence of reported gross margin and FCF margin data reduces transparency on operating efficiency, which is weaker than peers that disclose clearer sustainability-linked cost discipline.

Net debt to EBITDA of 0.41 suggests modest balance-sheet leverage, which can support environmental compliance spending, though this is not a direct environmental advantage versus peers.

No Tier 1 filing evidence was provided on emissions, energy use, or waste, so environmental positioning remains difficult to distinguish from peers on disclosed material metrics.

Social

Score:

No disclosed R&D intensity or workforce metrics were provided, limiting assessment of talent retention, safety, and human-capital investment relative to peers.

Zero stock-based compensation to revenue in the supplied data suggests limited dilution pressure, but it does not by itself demonstrate stronger employee alignment than peers.

The lack of reported social controversy, litigation, or incident data prevents evidence of a peer-leading social profile, keeping the assessment at a moderate level.

Without filing-based disclosure on diversity, training, or patient/consumer outcomes, RNTX cannot be shown to outperform peers on the most material social factors.

Governance

Score:

Zero stock-based compensation to revenue indicates restrained equity-based pay usage, which can reduce governance concerns versus peers with heavier dilution-linked compensation.

Debt to equity is reported at zero and net debt to EBITDA at 0.41, suggesting conservative leverage that typically lowers governance and refinancing risk relative to peers.

However, the absence of filing data on board independence, audit oversight, and shareholder rights limits evidence of stronger governance than peers.

Because the supplied metrics omit executive pay structure and control provisions, governance appears acceptable but not clearly superior on disclosed peer-comparable factors.

Overall Score

Score:

RNTX appears broadly middle-of-pack versus peers because the supplied data show conservative leverage and limited compensation pressure, but disclosure gaps prevent a stronger ESG ranking.

Score Driver: Limited Peer-Comparable ESG Disclosure

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Rein Therapeutics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →